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Background: MetastamiRs have momentous clinical relevance and have been correlated with disease progression
in many tumors. In this study, we identified neuroblastoma metastamiRs exploiting unique mouse models of
favorable and high-risk metastatic human neuroblastoma. Further, we related their deregulation to the modulation
of target proteins and established their association with clinical outcomes.
Results: Whole genome miRNA microarray analysis identified 74 metastamiRs across the manifold of metastatic tumors.
RT-qPCR on select miRNAs validated profile expression. Results from bio-informatics across the ingenuity pathway,
miRCancer, and literature data-mining endorsed the expression of these miRNAs in multiple tumor systems and showed
their role in metastasis, identifying them as metastamiRs. Immunoblotting and TMA-IHC analyses revealed alterations in
the expression/phosphorylation of metastamiRs’ targets, including ADAMTS-1, AKT1/2/3, ASK1, AURKβ, Birc1, Birc2, Bric5,
β-CATENIN, CASP8, CD54, CDK4, CREB, CTGF, CXCR4, CYCLIN-D1, EGFR, ELK1, ESR1, CFOS, FOSB, FRA, GRB10, GSK3β, IL1α,
JUND, kRAS, KRTAP1, MCP1, MEGF10, MMP2, MMP3, MMP9, MMP10, MTA2, MYB, cMYC, NF2, NOS3, P21, pP38, PTPN3,
CLEAVED PARP, PKC, SDF-1β, SEMA3D, SELE, STAT3, TLR3, TNFα, TNFR1, and VEGF in aggressive cells ex vivo and in a
manifold of metastatic tumors in vivo. miRNA mimic (hsa-miR-125b, hsa-miR-27b, hsa-miR-93, hsa-miR-20a) and inhibitor
(hsa-miR-1224-3p, hsa-miR-1260) approach for select miRNAs revealed the direct influence of the altered metastamiRs
in the regulation of identified protein targets. Clinical outcome association analysis with the validated metastamiRs’
targets corresponded strongly with poor overall and relapse-free survival.
Conclusions: For the first time, these results identified a comprehensive list of neuroblastoma metastamiRs, related
their deregulation to altered expression of protein targets, and established their association with poor clinical
outcomes. The identified set of distinctive neuroblastoma metastamiRs could serve as potential candidates for
diagnostic markers for the switch from favorable to high-risk metastatic disease.
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Neuroblastoma (NB), the most common cancer at infancy
[1, 2] accounts for about one tenth of pediatric cancer
deaths [3–5]. Despite significant advances in understanding
the biology of NB and, improved clinical outcomes in the
last decade [3, 5], the outcomes for high-risk groups still* Correspondence: naravind@ouhsc.edu
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remarkable heterogeneity, resistance and, poor hematological
reserve is extremely rare. Almost half of patients with
high-risk NB will relapse with hematogenous metastasis
[6] despite intensive multimodal therapy [3, 5, 7–14].
Compared with those with low/intermediate-risk disease
(65 %), the five-year overall survival (OS) of patients with
high-risk disease is low (<10 %). The rate of long-term
survival is even more dismal ten years after diagnosis, with
only 2 % OS for patients with stage 4 disease [13, 15].
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origin, intravasation, extravasation and colonization, be-
fore they will grow and proliferate at a secondary site and
form a new tumor [16, 17]. The capability of cancer cells
to metastasize depends on genetic and epigenetic events
that are acquired during tumor progression [18]. Despite
great advancements in our knowledge of metastasis biol-
ogy, the molecular mechanisms are still incompletely
understood. Remarkably, the regulatory role for miRNAs
in metastasis has been established [19–23]. Thus, these
miRNAs have been identified as metastamiRs [24], as they
have both pro- and anti-metastatic effects. Accordingly,
we used a unique, MYCN non-amplified mouse model of
human high-risk aggressive metastatic neuroblastoma
coupled with whole genome miRNA approach to investi-
gate the functional reorganization of metastamiRs in NB
progression.
Genomic amplification of MYCN plays a dominant role
in determining the biologic behavior of neuroblastoma and
is strongly associated with advanced stage of the disease,
rapid tumor progression, therapy resistance and overall
poor prognosis [25–29]. However, the realm of MYCN
amplification is restricted to about 20 % of all cases of
neuroblastoma [26, 30, 31], ~30-40 % of stage 3 and stage 4
and only ~10 % of stage 4 s patients [29, 32]. Critically, the
lack of MYCN amplification without either 1p loss or 17q
gain further limits the role of MYCN in distinguishing
those patients who are likely to survive from those that are
destined to fail treatment [33].Moreover, long-term sur-
vival of advanced neuroblastoma patients with MYCN
amplification has also been reported [34]. Conversely, prog-
nostic insights and molecular drivers of the MYCN non-
amplified high-risk neuroblastoma, that comprises about
60-70 % of stage 3 and stage 4 disease remains unexplored.
More importantly, MYCN expression does not correlate
with the prognosis of adverse outcome in advanced-stage
neuroblastoma with non-amplified MYCN [35]. In this re-
gard, we utilized, MYCN non-amplified cell-line (SH-SY5Y)
derived mouse model of human high-risk aggressive meta-
static neuroblastoma to define the functional reorganization
of metastamiRs in neuroblastoma progression.
miRNAs are endogenous, hairpin-shaped, small non-
coding single-stranded RNAs of ∼22 nucleotides in length;
they serve as post-transcriptional regulators of gene expres-
sion [36]. Although miRNAs were initially considered non-
functional, recent studies documented the potential of
miRNAs to control cell fate [37–39], as well as their conser-
vation across species [40, 41], expression in different tissues
and cell types, and their involvement in every biological
process. miRNAs function as guide molecules by base
pairing with the target mRNA, inducing translation repres-
sion or transcripts cleavage [42]. Consequently, miRNA de-
regulation is a hallmark of several pathological conditions,
including cancer.MetastamiRs are regulatory miRNAs which promote or
suppress various steps in the migration and metastasis of
cancer cells [24]. It seems that these metastasis-associated
miRNAs do not influence primary tumors in either the
development or initiation steps of tumorigenesis, but they
regulate key steps in the metastatic program and pro-
cesses, such as EMT, apoptosis, and angiogenesis. Emer-
ging evidence continually recognizes tumor-specific
metastamiRs in many tumor models, including breast,
lung, prostate, colorectal, gastric, and head and neck can-
cer. However, in the context of neuroblastoma, no metas-
tamiRs have been grouped or identified. Altered
expression of select miRNAs (http://mircancer.ecu.edu)
has been shown to exert a causal role in metastasis
[20, 22, 23, 43–51]. It is noteworthy that these studies focus
on a single miRNA manipulation approach, underscoring
the metastatic response through a single gene target. Con-
sidering the complexity of sequential steps involved in me-
tastasis, it is necessary to ascertain all causal metastamiRs
that play crucial roles in NB metastasis. To our know-
ledge, this is the first of such an endeavor in the neuro-
blastoma setting. The results of this study comprehensively
identified 74 metastamiRs from whole genome miRNA
profiles of a manifold of metastatic tumors from a unique
clinically translatable mouse model of aggressive high-risk
NB. Further, this study determined the translation of these
metastamiR reorganizations into the functional down-
stream response, that is, target proteins translation that
defines metastasis, and the influential role of metastimiRs
in clinical outcomes.
Results
Spontaneous and reproducible high-risk metastatic
disease in vivo
Human neuroblastoma cell-line, SH-SY5Y is the third
sub-line of SK-N-SH (SK-N-SH→ SH-SY→ SH-SY5→
SH-SY5Y) that contains both neuroblast-like (N-type)
floating and substrate-adherent (S-type) epithelial-like
cells [52]. More importantly, SH-SY5Y cells are unique
MYCN non-amplified cells. Xenotransplantation of SH-
SY5Y cells resulted in the development of ~200 mm3 xe-
nografts in ~70 % of the animals within 30 days (Fig. 1a)
[53, 54]. About 30 % of the mice that received identical
clones initially (within 10–20 days) showed xenograft de-
velopment, then subsided to a residual tumor (Fig. 1a).
However, over an extended 50–60 day period, these mice
suddenly gained weight and presented with multiple
clinically-mimicking metastatic tumors in the mediasti-
num and retroperitoneal, pelvic, abdominal, and chest
cavities (Fig. 1a). These mice generally produced 5–12
large, viable, often multi-lobular tumors in multiple sites
with well-organized blood supplies (Fig. 1a). This aggres-
sive disease with metastatic dissemination developed
over a short period (1–2 weeks) and vigorously, as
Fig. 1 Comparative miRNA profiling in non-metastatic primary xenografts and the manifold of metastatic tumors from animals bearing aggressive
neuroblastoma. a Representative mice showing non-metastatic xenograft and high-risk aggressive metastatic disease. Plate showing tumors
harvested from multiple metastatic sites. b Schematic representation showing relative tumorigenic capacity and aggressive disease formation
of parental SH-SY5Y and metastatic site derived aggressive cells (MSDACs). Subcutaneously injecting MSDACs produced large xenograft with
multiple metastatic tumors in retroperitoneal, pelvic, abdominal, and chest cavities. c Traverse analysis of whole genome miRNA expression
between non-metastatic (X-NB) and aggressive disease (AD) animals. Total of 852 miRNAs were compared between groups and their alterations
are color coded (Red – upregulated; Blue – down regulated). Total number of altered molecules under each comparison is provided in the
corresponding box. Numbers in the parenthesis are the molecules that are significantly (> or < 2 fold) modulated
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aging. Parallel xenotransplanted animals with no tumor
dissemination to distant sites over the extended period
served as the non-metastatic controls.
Metastatic Site Derived Aggressive cell (MSDAC) clones
derived from the manifold of metastatic tumors werediscretely characterized by karyotyping, whole genome
array CGH analysis, and tumorosphere-forming capacity
(data reported elsewhere). MSDACs are relatively small and
spherical with thin neurites. Administration of MSDACs
produced >500 mm3 tumors (wet weight 2.40 ± 1.30 g),
compared with the <150 mm3 xenografts (0.20 ± 0.04 g)
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mice that received MSDACs presented with multiple meta-
static tumors in the retroperitoneal, pelvic, abdominal, and
chest cavities, demonstrating the reproducibility of the ag-
gressive disease. Conversely, the mice that received parental
cells did not exhibit any distant metastasis.
Reorganization of metastamiRs in high-risk metastatic
disease
To define the miRNAs’ modulations in the evolution of
high-risk neuroblastoma and to identify crucial players
(metastamiRs) that orchestrate metastasis, we adopted a
whole genome miRNA profiling approach. A total of 852
functional transcripts were assayed in triplicate for each
condition. Traverse analysis between the non-metastatic
controls to the manifold of metastatic tumors not only
recognized unique animal/tumor-specific expression sig-
natures, but also identified clusters of miRNAs that were
commonly up-or downregulated (Fig. 1c). Overall, of the
852 transcripts analyzed, we observed an upregulation of
226, 483, 202, 363 (when compared with X-NB-1), 378,
680, 359, and 488 (compared with X-NB-2) miRNAs in
metastatic tumors. Applying stringent criteria (>2 fold),
a total of 98, 168, 117, 179 (vs. X-NB-1), 145, 377, 161,
and 292 (vs. X-NB-2) miRNAs were significantly upregu-
lated in the metastatic tumors. Evidently, 52 (vs. X-NB-
1) and 67 (vs. X-NB-2) miRNAs were upregulated across
all the metastatic tumors investigated. Upregulation of
52 miRNAs remained consistent across the metastatic
tumors, irrespective of the comparisons to the non-
metastatic controls (Fig. 2). Conversely, a total of 621,
365, 646, 486 (vs. X-NB-1), 467, 165, 491, and 362 (vs.
X-NB-2) miRNAs were downregulated in metastatic tu-
mors. Significantly (>2 fold), 544, 253, 587, 434 (vs. X-
NB-1), 380, 95, 396, and 304 (vs. X-NB-2) miRNAs were
completely suppressed in the metastatic tumors. More
importantly, 137 (vs. X-NB-1) and 23 (vs. X-NB-2) miR-
NAs were downregulated across all metastatic tumors.
Remarkably, downregulation of 22 miRNAs persisted
across the metastatic tumors, irrespective of the traverse
comparisons to the controls (Fig. 3a).
To validate the altered expression levels observed with
whole genome miRNA array, we examined the expression
levels of select miRNAs including hsa-miR-1260, hsa-
miR-1224-3p (showing significant upregulation; see Fig. 2),
hsa-miR-93, hsa-miR-20a, hsa-miR-125b, hsa-miR-27b
(showing significant downregulation; see Fig. 3a), using in-
dividual miRNA QPCR analysis. Compared to the non-
metastatic xenograft, we observed a complete (P < 0.001)
decrease in the expression of hsa-miR-93, hsa-miR-20a,
hsa-miR-125b, and hsa-miR-27b (Fig. 3b). Conversely, we
observed a significant (P < 0.001) upregulation of hsa-
miR-1260 and hsa-miR-1224-3p in metastatic tumor com-
pared with the non-metastatic control (Fig. 3b). Thesedata are consistent with the observed expression levels of
these miRNAs using the whole genome approach.
Altered expression of the target (metastasis-related)
proteins validates the translation of the functional
response of the neuroblastoma metastamiRs
To further substantiate our findings, we investigated the
expression levels of target proteins of the identified
metastamiRs. Since metastasis is a complex processes,
and as we identified a total of 74 metastamiRs in this
setting, we examined a total of 49 targets that are in-
volved in tumor progression, i.e., metastasis, in MSDACs
and a manifold of metastatic tumors. MetastamiRs regu-
lating these targets and their expression status in our
study are presented in Table 1 (color-coded). In
MSDACs grown ex vivo, we observed an induced ex-
pression of ADAMTS-1, CASP8, CDK4, CTGF,
CYCLIN-D1, ELK1, ESR1, CFOS, FRA, IL-1α, JUND,
kRAS, MCP1, MMP2, MMP3, MMP9, MMP10, cMYC,
SELE, TNFα, and VEGF, and phosphorylation of AKT1/
2/3, NOS3, p38, and EGFR compared with the parental
SH-SY5Y cells (Fig. 4a). Compared with the non-
metastatic xenograft controls, we observed a robust in-
crease in ADAMTS-1, ASK1, AURKβ, Birc1, Birc2,
Birc5, CD54, CDK4, CTGF, CXCR4, CYCLIN-D1, EGFR,
ELK1, ESR1, CFOS, FRA, GRB10, pGSK3β, IL1α, JUND,
KRTAP1-1, MEGF10, MMP2, MMP3, MMP9, MMP10,
MTA2, MYB, cMYC, NF2, P21, PTPN3, CLEAVED
PARP, PKC, SDF-1β, SEMA3D, SELE, STAT3, TNFα,
TNFR1, and VEGF expression, as well as AKT1/2/3 and
NOS3 phosphorylation in the manifold of metastatic tu-
mors (Fig. 4b and c).
We then sought to define and typify the target alter-
ations in aggressive neuroblastoma. We used a custom-
made TMA constructed with a manifold of tumors from
the metastatic sites of several animals coupled with non-
metastatic xenograft controls. These were subjected to
automated IHC and image analysis for select targets, in-
cluding MEGF10, KRTAP1-1, SEMA3D, MYC, and
GRB10. Consistent with our immunoblotting observa-
tions under ex vivo and in vivo conditions, MEGF10,
KRTAP1-1, SEMA3D, MYC, and GRB10 IHC staining
revealed relatively strong positivity in metastatic tumors
(Fig. 5). Multiple EGF-like-domains-10 (MEGF10) posi-
tive staining appeared in brown, and was predominantly
localized in plasma membranes in a punctuated pattern
(Fig. 5). MEGF10 immunoreactivity was barely detect-
able in non-metastatic NB xenografts. However, the
manifold of metastatic tumors exhibited significantly
high immunoreactivity for MEGF10 localization (Fig. 5).
Keratin-associated protein family 1–1 (KRTAP1-1) posi-
tivity appeared in brown, and was predominantly local-
ized in the cytoplasm (Fig. 5). Consistent with our
immunoblotting data, we observed a profound and
Fig. 2 Activated miRNAs in high-risk metastatic neuroblastoma. Histograms showing the expression profile of 52 miRNAs that were significantly (>2
fold) up regulated across the metastatic tumors of the animals with aggressive disease. Data mining was performed using traverse analysis comparing
each non-metastatic control to that of the aggressive disease profiles
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KRTAP1-1 in the metastatic tumors as opposed to the
non-metastatic controls (Fig. 5). Likewise, Semaphorin-
3D (SEMA-3D) IHC exhibited moderate cytoplasmic
positivity with a dark brown color (Fig. 5). Compared
with the non-metastatic controls, increased expression
of SEMA-3D was evident in almost all metastatic tu-
mors analyzed. MYC-IHC revealed strong nuclearpositivity in all tumors analyzed. We observed a mar-
ginal increase in MYC expression in the metastatic tu-
mors when compared with non-metastatic controls
(Fig. 5). Growth factor receptor-bound protein 10
(GRB10) IHC revealed high levels of localization in non-
metastatic neuroblastoma tissues. Notably, immunoreac-
tivity was highly intense and significant (P < 0.001) in
metastatic tumors (Fig. 5). The positive staining of
Fig. 3 Regulated miRNAs in high-risk metastatic neuroblastoma. a Histograms showing the expression profile of 22 miRNAs that were
significantly (<2 fold) down regulated across the metastatic tumors of the animals with aggressive disease. Data mining was performed using
traverse analysis comparing each non-metastatic control to that of the aggressive disease profiles. b miRNA RT-qPCR analysis showing the
complete regulation of Hsa-miR-93, Hsa-miR-20a, Hsa-miR-125b and Hsa-miR-27b and, significant increase in the expression of Hsa-miR-1260
and Hsa-miR-1224-3p in metastatic tumors as compared to the non-metastatic xenograft
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localized in the cytoplasm.
These observations were consistent across tumors
from the same animal as well as tumors from different
animals. We observed similar alterations in the expres-
sion of MEGF10, KRTAP1-1, SEMA3D, MYC, and
GRB10 in the manifold of distant tumors reproducedfrom aggressive disease-bearing animals. Aperio image
analysis coupled with PRISM stats were used to demon-
strate the increased expression of these target proteins
in the tumors of animals with aggressive disease, but
not in the non-metastatic xenografts (Fig. 5). Ex vivo
and in vivo upregulation of these targets, which are
well—documented candidates for metastasis and tumor
Table 1 Targets analyzed by the western-blot and the expression status (color coded) of the corresponding metastamiRs in high-
risk metastatic neuroblastoma
ADAMTS-1 miR-1224-3p, miR-1260, miR-125b
ASK1 miR-1258, miR-1243, miR-519c-3p, miR-1224-5p, miR-20a, miR-93, miR-1260, miR-23a*, miR-30b*
AURK ß miR-765
BIRC2 miR-500*
cMYC let-7a, let-7b, let-7c, let-7e, let-7f, let-7g, miR-98
CASP8 miR-519c-3p, miR-143*, miR-20a, miR-93, miR-1224-3p





CREB miR-190, miR-190b, miR-1224-5p, miR-20a, miR-93, miR-125b, miR-27b
CTGF miR-30c-1*, miR-576-3p, miR-383, miR-143*, miR-30b*
CXCR4 miR-1, miR-206
CYCLIN D1 let-7a, let-7b, let-7c, let-7e, let-7f, let-7g, miR-98, miR-383, miR-1269, miR-1, miR-206, miR-20a, miR-93, miR-23a*, miR-608
EGFR miR-664*, miR-1250, miR-1269, miR-1, miR-206, miR-149*, miR-27b, miR-1909*, miR-608
ELK1 miR-1260, miR-125b, miR-765, miR-1321, miR-608
NOS3 miR-887, miR-1244, miR-765
ESR1 miR-188-5p, miR-190, miR-190b, miR-1182, miR-519c-3p, miR-1, miR-206, miR-148b, miR-20a, miR-93, miR-1909*
E-SELECTIN miR-593
FOS B miR-766, miR-1, miR-206, miR-148b, miR-1224-3p, miR-1260, miR-23a*, miR-765, miR-27b, miR-1909*, miR-608
FRA miR-593, miR-149*
GRB10 miR-519c-3p, miR-513a-5p, miR-30b*, miR-125b
IL-1α miR-149*, miR-30b*
JUN D miR-1, miR-206, miR-1321
kRAS let-7a, let-7b, let-7c, let-7e, let-7f, let-7g, miR-98, miR-1243, miR-143*, miR-513a-5p, miR-1, miR-206,
miR-200b, miR-30b*, miR-27b
KRTAP1-1 miR-601, miR-1258, miR-143*, miR-23a*
MCP1 miR-664*, miR-593, miR-1, miR-206
MEGF10 miR-190, miR-190b, miR-1258, miR-383
MMP10 miR-32*, miR-32, miR-367*, miR-148b




NF2 miR-1909*, miR-32*, miR-32, miR-367*, miR-608
GSK3B miR-624*, miR-1, miR-206, miR-23a*, miR-27b
P38 miR-1258, miR-1243, miR-513a-5p, miR-125b, miR-27b
P21 miR-92a-2*, miR-32*, miR-32, miR-367*, miR-20a, miR-93, miR-765, miR-608
AKT2 miR-200b, miR-148b, miR-1224-3p, miR-1260, miR-1909*, miR-608
AKT3 miR-320b, miR-320c, miR-149*, miR-20a, miR-93
PKC miR-30b*, miR-1321, miR-1909*
PTPN3 miR-593, miR-20a, miR-93, miR-765, miR-27b
SDF-1ß miR-624*, miR-1182, miR-519c-3p, miR-1260, miR-23a*, miR-765, miR-1909*
SEMA3D miR-432, miR-1268, miR-1321
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Table 1 Targets analyzed by the western-blot and the expression status (color coded) of the corresponding metastamiRs in high-
risk metastatic neuroblastoma (Continued)
STAT3 let-7a, let-7b, let-7c, let-7e, let-7f, let-7g, miR-98, miR-1244, miR-20a, miR-93, miR-125b, miR-1909*, miR-608
SURVIVIN miR-1182, miR-1321
TNFR1 miR-766
TNF-α miR-125b-1*, miR-519c-3p, miR-1909*
VEGF miR-383, miR-1, miR-206, miR-200b, miR-20a, miR-125b, miR-27b
Up regulated; Down Regulated
Fig. 4 Modulation of metastamiRs target proteins in MSDACs ex vivo and in metastatic tumors in vivo. Immunoblots showing the expressional
modulation of key metastatsis and tumor progression related protein targets of the identified metastamiRs in (a) parental SH-SY5Y cells vs MSDACs
under ex vivo conditions and; (b and c) non-metastatic xenograft vs manifold of metastatic tumors from aggressive disease animals in vivo
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Fig. 5 Localization and expressional modulation of metastamiRs target proteins in metastatic neuroblastoma. Representative image of the tissue micro
array constructed with the replicates of non-metastatic xenografts controls and the manifold of metastatic tumors from spontaneous aggressive disease as
well as the reproduced aggressive disease animals. Automated IHC stained panels showing the staining pattern and cellular localization of the metastamiRs’
protein targets (GRB10, MYC, SEMA3D, KRTAP1-1, MEGF10) in tumor samples. Histograms of Aperio-Spectrum image analysis and quantification of positivity
for each target protein analyzed across the metastatic tumors of various animals presented with aggressive disease. The positivity values are compared to
the non-metastatic xenograft controls using ANOVA with Tukey’s post-hoc correction using GraphPad PRISM
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this study, underscores the translation of the functional
response (metastasis) of metastamiRs in this setting.
Altered miRNAs dependent regulation of functional
targets
Further to define the direct role of the deregulated
miRNAs of high-risk aggressive disease in the regula-
tion of the target proteins that demonstrated profound
alterations both in the metastatic tumors in vivo and
in MSDACs ex vivo we examined the corresponding
alterations of the target proteins after functionallymimicking or inhibiting miRNAs. First, MSDACs tran-
siently transfected with mimics for hsa-miR-125b, hsa-
miR-27b, hsa-miR-93 or hsa-miR-20a (those exhibited
complete suppression in aggressive disease) and exam-
ined for the regulation of their corresponding target
proteins (Fig. 6a). High-throughput quantitative confo-
cal immunofluorescence demonstrated a significant
(P < 0.001) inhibition of MMP2, p38, TNFα and VEGF
in MSDACs in the presence of hsa-miR-125b mimic
(Fig. 6bi). In addition, we observed a marginal decrease
in GRB10 and STAT3 expression with hsa-miR-125b
mimic. Similarly, functionally mimicking hsa-miR-27b
Fig. 6 MetastamiRs dependent regulation of functional protein targets. a Operetta high-content confocal imaging showing immunofluorescence
of ADAMTS-1, ASK-1, CREB, FOSB, GRB10, kRAS, MMP2, MMP3/10, p38, AKT, PTPN3, STAT3, TNFα and VEGFa in MSDACs. b Histograms of mean
cell–Alexa Fluor intensity obtained from Columbus automated batch analysis showing alterations in the expression (i) GRB10, MMP2, p38, STAT3, TNFα
and VEGF in cells with hsa-miR-125b mimic, (ii) EGFR FOSB, kRAS, p38, PTPN3 and VEGF in hsa-miR-27b mimic transfected cells, (iii) ASK1, CREB, MMP2,
MMP3/10, PTPN3, STAT3and VEGF in MSDACs with hsa-miR-20a mimic and, (iv) MMP2, MMP3/10, PTPN3 and STAT3 with hsa-miR-93 mimic in MSDACs.
c Histograms of mean cell–Alexa Fluor intensity showing alterations in the expression of (i) ADAMTS-1 and CREB with hsa-miR-1224-3p inhibition and, (ii)
ADAMTS-1, ASK1, FOSB and AKT-1 with hsa-miR-1260 inhibition. Group-wise comparisons were performed with ANOVA with Tukey’s post-hoc correction
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kRAS, p38 and PTPN3 (Fig. 6bii). Interestingly, mimick-
ing hsa-miR-27b did not inhibit the expression of EGFR
and VEGF in MSDACs. On the other hand, MSDACs
transfected with hsa-miR-20a exhibited significant (P <
0.001) inhibition of ASK1, MMP2, MMP3/10, PTPN3
and VEGF (Fig. 6biii). We did not see any consistent
inhibition of CREB and STAT3 at least with the mimic
for hsa-miR-20a. Moreover, hsa-miR-93 mimic exhibited
statistically significant inhibition of MMP2, MMP3/10,
PTPN3 and STAT3 in this setting (Fig. 6biv). Next,
MSDACs transiently transfected with inhibitors for hsa-
miR-1224-3p or hsa-miR-1260 (both showed profoundinduction in metastatic tumors) and examined for the
alterations in protein targets. Inhibiting hsa-miR-1224-
3p resulted in the significant (P < 0.001) induction of
ADAMTS-1 and CREB (Fig. 6ci). Like-wise, inhibiting
hsa-miR-1260 markedly (P < 0.001) induced ADAMTS-1
and ASK1 (Fig. 6cii). However, inhibiting hsa-miR-1260
did not result in the induction of FOSB and AKT-1 in
this setting. Together, these results clearly demonstrate
the direct role of altered miRNAs observed in high-risk
aggressive disease in the regulation of the protein tar-
gets identified in this setting and, thereby validates the
translation of functional response of the neuroblastoma
metastamiRs.
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To determine the relevance of metastamiRs in aggressive
disease, we first clarified their role in cancer biological
functions, network and communal molecular orchestra-
tions, and tumor progression. For the miRNAs that were
reorganized in high-risk NB, IPA “Core-Analysis” identi-
fied multiple networks classifying their roles in diseases
including cancer and their specific functions (Additional
file 1: Figure S1). Functionally, these miRNas were shown
to be intrinsically involved in cell death and cell survival,
inflammation, the cell cycle, cellular movement, DNA
replication, recombination and repair, cell-to-cell sig-
naling and interaction, and cellular growth and prolifer-
ation. These processes play defined roles in metastasis
(Additional file 1: Figure S1). Convergence of all of the
miRNA networks at the processes that endorse metas-
tasis identify the altered miRNAs as metastamiRs. To
further validate whether these miRNAs are recognized
as metastamiRs in other tumor systems, we used the
cancer miRNA profile database from mircancer.ecu.edu
(release version of miRCancer June 2014), ingenuity
pathway analysis of diseases and biological functions,
and a manual literature survey.
Of the 74 metastamiRs, data mining in miRCancer iden-
tified at least 36 that were altered: hsa-let-7a, hsa-let-7b,
hsa-let-7c, hsa-let-7e, hsa-let-7f, hsa-let-7 g, hsa-mir-1,
hsa-mir-100, hsa-mir-122, hsa-mir-1250, hsa-mir-1258,
hsa-mir-125b, hsa-mir-1280, hsa-mir-143, hsa-mir-148b,
hsa-mir-149, hsa-mir-190b, hsa-mir-200b, hsa-mir-206,
hsa-mir-20a, hsa-mir-220a, hsa-mir-23a, hsa-mir-27b,
hsa-mir-29b-1, hsa-mir-30b, hsa-mir-30c-1, hsa-mir-32,
hsa-mir-383, hsa-mir-432, hsa-mir-500, hsa-mir-601, hsa-
mir-656, hsa-mir-765, hsa-mir-886-3p, hsa-mir-92a, and
hsa-mir-93. Alterations in these metastamiRs were found
in one or more of the following tumor systems: acute
lymphoblastic leukemia, acute myeloid leukemia, acute
promyelocytic leukemia, b-cell lymphoma, bladder cancer,
breast cancer, bronchioloalveolar carcinoma, cervical can-
cer, cholangiocarcinoma, chronic lymphocytic leukemia,
colon cancer, endometrial cancer, esophageal squamous
cell carcinoma, follicular cancer, gastric cancer, glioblast-
oma, head and neck squamous cell carcinoma, hepatocel-
lular carcinoma, laryngeal squamous cell carcinoma, liver
cancer, lung cancer, malignant melanoma, mantle cell
lymphoma, medulloblastoma, mesenchymal cancer, naso-
pharyngeal cancer, neuroblastoma, non-small cell lung
cancer, oral squamous cell carcinoma, osteosarcoma, ovar-
ian cancer, ovarian carcinoma, pancreatic cancer, papillary
thyroid carcinoma, pituitary carcinoma, prostate cancer,
renal cell carcinoma, thyroid cancer, and tongue cancer
(data not shown).
Ingenuity pathway analysis, however, identified the ex-
pressional association of these metastamiRs in at least
eighty different tumor systems (Additional file 2: Figure S2).Armed with the above information, we further explored the
crucial role of metastamiRs in tumor cell metastasis.
Additional file 5: Table S1 shows the list of identified miR-
NAs, their functions in the context of metastasis and tumor
progression as per the published evidence, total number of
their gene targets, and the references from which we ob-
tained this information. Interestingly, almost all of the miR-
NAs identified in our high-risk metastatic neuroblastoma
have been well characterized in terms of metastasis regula-
tion (Additional file 5: Table S1), which could identify them
as metastamiRs.Alterations in the targets of the identified metastamiRs
are associated with poor clinical outcomes
To demonstrate the functional relevance of these metas-
tamiRs to high-risk metastatic neuroblastoma and poor
clinical outcomes, we examined the correlation of indi-
vidual expression of their gene targets with overall sur-
vival (OS) in patients with neuroblastoma. Utilizing the
gene expression data for a cohort of 88 human neuro-
blastoma patients, we examined the prognostic values
for a total of 22 gene targets that had validated expres-
sion levels in our model. Kaplan-Meier plots showed a
significant association between increased expression of
ELK1, CDK4, MMP2, AURKβ, FRA, MYB, JUND,
BIRC5, AKT2, SELE, TNFα (Additional file 3: Figure
S3), NOS3, ESR1, KRTAP1-1, MMP3, MMP9, NF2,
CXCR4, ADAMTS1, VEGF, CD54, EGFR, and AKT1
(Additional file 4: Figure 4) and poor OS in patients with
neuroblastoma. This inverse association also reflects
poor relapse-free survival in these patients (data not
shown). Interestingly, there was a definite association be-
tween CREB1 loss and poor OS (Additional file 3: Figure 3).
This CREB1 loss also resulted in poor relapse-free sur-
vival in children with neuroblastoma. Clinical outcome
association analysis revealed a strong correlation be-
tween the increased expression of the genes listed above
and stage progression, favorable→ unfavorable disease
and alive→ died-of-disease (data not shown). Together,
these data demonstrate the alterations of gene targets by
the reorganization of metastamiRs in high-risk meta-
static disease that drives poor clinical outcomes in chil-
dren with neuroblastoma.Discussion
About 60 % of neuroblastoma patients with high-risk
disease will relapse with hematogenous metastasis [6],
despite intensive multimodal therapy [3, 5, 7–14].
Neuroblastoma is derived from embryonic neural crest
cells that have a high potential to migrate. Since meta-
static NB has a high mortality rate, understanding the
molecular mechanism flow-through that is involved in
neuroblastoma cell invasion and metastasis will help us
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particularly when we use appropriate clinically translat-
able animal models. In vitro and in vivo approaches have
identified numerous molecular markers that play crucial
roles in the functional orchestration of neuroblastoma
metastasis [19, 55–58]. After Ma and colleagues [32]
demonstrated that miRNAs were the upstream regula-
tors of the complex invasion-metastasis network in
breast cancer, researchers began to uncover the roles of
miRNA(s) in highly metastatic neuroblastoma [59, 60].
Transcriptome regulation occurs via miRNAs through
multiple processes, including translational inhibition,
destabilization, or RNA decay [33], all of which are con-
sidered important modulators of signal transduction
pathways in metastatic progression.
Studies delineating the regulatory role of the miRNA
in neuroblastoma metastasis have thus far been limited
to the understanding of a single miRNA-associated tar-
get molecule’s dependent functions along the axis of me-
tastasis [22, 43, 45, 46, 61]. Considering the complexity
of the sequential steps involved in neuroblastoma metas-
tasis, it is crucial to define the functional role of every
miRNA (metastamiR) that plays a vital role in each step
of metastasis. For the first time, utilizing a clinically
translatable animal model of high-risk metastatic neuro-
blastoma, we have identified the cluster of metastamiRs,
their functional translation in terms of target protein ex-
pression, and the association of such alterations with
clinical outcomes.
In the current study, we used multiple complementary
methodologies to identify neuroblastoma metastamiRs.
First, this study employed a unique clinically translat-
able, reproducible mouse model of human high-risk
metastatic neuroblastoma coupled with whole genome
miRNA array technology. We screened differentially
expressed miRNAs in metastatic tumors as opposed to
non-metastatic tumors. We observed significant inter-
animal variations in up-and downregulated miRNAs and
under less stringent and more stringent conditions (see
Fig. 1c). Examining this topic further, we validated the
most distinctly deregulated over- and under—expressed
miRNAs by RT-qPCR, utilized traverse analysis of al-
tered miRNAs between the sample groups, characterized
the reorganized miRNAs by compiling their interactions
in ingenuity pathway analysis, expression in multiple
tumor systems, and their functional role in metastasis
and tumor progression. Further, we performed miRNA-
target analysis, comprehensively identified the alterations
in the expression and cellular localization of the target
proteins in ex vivo and in vivo metastatic cells, recog-
nized the direct influence of the altered miRNAs on the
regulation of target proteins with mimic/inhibitor ap-
proach, and compiled the target proteins’ association
with neuroblastoma patient outcomes.Since the main objective was to identify the defined
metastamiRs of neuroblastoma, we compared the
traverse examination of four aggressive disease expres-
sion profiles to that of non-metastatic profiles to derive
clear evidence of differential expression without equivo-
cal outcomes. Interestingly, the outcome of the present
work confirmed some findings from other neuroblastoma
miRNA studies (http://mircancer.ecu.edu/browse.jsp) [59],
but also essentially identified many new metastamiRs in
this setting. Of the 74 metastamiRs identified in this
study, we found an overlap of 16 metastamiRs, includ-
ing Hsa-miR-148b, Hsa-miR-23a, Hsa-miR-100, Hsa-
miR-93, Hsa-miR-125b, Hsa-miR-98, Hsa-miR-92a,
Hsa-miR-29b, Hsa-miR-30c, Hsa-let-7a, Hsa-let-7b,
Hsa-let-7c, Hsa-let-7e, Hsa-let-7f, and Hsa-let-7g, with
the findings of other researchers. To our knowledge,
this is the first such attempt to identify all-inclusive
miRNAs that could play defined roles in metastasis,
their functional translation, and their association with
clinical outcomes, at least in the neuroblastoma setting.
Almost all studies that investigated miRNA roles in
neuroblastoma metastasis focused on understanding a
single molecule. As discussed above, our approach to
identify new metastamiRs in the neuroblastoma setting
is directly related to the lack of any comprehensive ap-
proach studies for neuroblastoma or other tumor types.
Limited overlap with similar studies in other cancers
[59] may reflect the use of different detection plat-
forms, miRBase releases, or tumor models or origins. In
addition, results that are based solely on microarray
data have a relatively high false-positive rate. Thus, we
validated our microarray results with RT-qPCR for
upregulation (Hsa-miR-1260; Hsa-miR-1224-3p) and
downregulation (Hsa-miR-20a, Hsa-miR-27b, Hsa-miR-
125b, Hsa-miR-93) profiles (see Fig. 3b).
Since it is important to characterize each of the reorga-
nized miRNAs in neuroblastoma metastasis, and this ac-
tivity was within the scope of this study, we extensively
investigated the role of each miRNA in tumor progression
and metastasis in multiple tumor systems, including
neuroblastoma. Regulation of these miRNAs has been
documented in many tumor systems and biological func-
tions, including metastasis (Additional file 2: Figure S2).
Though it is not practical to discuss each miRNA, we
compiled their biological functions in the light of the pub-
lished evidence that identifies them as metastamiRs
(Additional file 5: Table S1). However, to understand their
precise function in neuroblastoma metastasis and since
expression profiles do not give us information about their
biological functions, we measured the expressional alter-
ations of key targets that were shown to play crucial roles
in metastasis. For the first time, we quantified the expres-
sion and phosphorylation of 49 target proteins. Further, to
capture the metastamiRs associated with translational
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sion in metastatic cells ex vivo and in the manifold of ag-
gressive metastatic tumors. The targets examined in the
study are regulated by more than one metastamiR identi-
fied in this setting (see Table 1). Thus, to the best of
our knowledge, the presented list of 49 deregulated
metastasis-related protein targets of metastamiRs provides
the most extensive list of neuroblastoma metastamiRs’ as-
sociated response. In this respect, the global approach in
our study to assess the expression data in the manifold of
metastatic tumors, all in the screening phase by microar-
rays, in the validation phase by RT-qPCR and response
validation by target protein expressions and their miRNA
dependent regulation, as mentioned above, proved to be
advantageous. We also applied clinical outcome associ-
ation analysis with the validated protein targets of the
identified metastamiRs in the neuroblastoma setting. In-
duced expression (ELK1, CDK4, MMP2, AURKβ, FRA,
MYB, JUND, BIRC5, AKT2, SELE, TNF-α, NOS3, ESR1,
KRTAP1-1, MMP3, MMP9, NF2, CXCR4, ADAMTS1,
VEGF, CD54, EGFR, and AKT1) and suppression (CREB1)
of metastamiRs’ target proteins corresponded strongly
with poor patient outcomes (Additional files 3: Figure S3
and Additional file 4: Figure S4).Conclusions
For the first time, this study of miRNAs profiles in non-
metastatic and metastatic neuroblastoma identified a com-
prehensive list of 74 deregulated metastasis-associated miR-
NAs, termed metastamiRs. We primarily recognized new
miRNAs associated with neuroblastoma metastasis, and
also confirmed the results of other studies, as only a few
miRNAs have been described as neuroblastoma metasta-
miRs. Further, our results demonstrated a significant modu-
lation in the expression of 49 key metastasis-regulating
protein targets of these metastamiRs in aggressive cells
ex vivo and in the manifold of metastatic tumors in vivo.
More importantly, the clinical outcome association analysis
corresponded with poor overall and relapse-free survival. In
conclusion, the current study identified a distinctive set of
neuroblastoma metastamiRs that could serve as potential
candidates for diagnostic markers for the switch from favor-
able to high-risk metastatic disease.Methods
Cell culture
The SH-SY5Y human neuroblastoma cell line was ob-
tained from ATCC (Manassas, VA) and was cultured
and maintained as described earlier [54]. For passaging
and for all experiments, the cells were detached using
0.25 % trypsin /1 % EDTA, re-suspended in complete
medium, counted (Countess, Invitrogen), and incubated
in a 95 % air/5 % CO2 humidified incubator.In vivo human neuroblastoma
experiments—development of reproducible non-
metastatic xenografts and mouse models of aggressive
metastatic disease
All animal experiments conformed to American Physio-
logical Society standards for animal care and were car-
ried out in accordance with guidelines laid down by the
National Research Council. All protocols were approved
by the University of Oklahoma Health Sciences Center
Institutional Animal Care and Use Committee and
adhered to the ARRIVE guidelines. Seven-week-old
athymic NCr-nu/nu nude mice (NCI, Frederick, MD) re-
ceived SC injections of 5x106 SH-SY5Y cells suspended
in Matrigel (BD Biosciences) into their right flank. Ani-
mals were observed for xenograft and/or aggressive
metastatic disease development for extended periods of
time (Min 15; Max 60 days). Tumor growth, regression,
and dissemination to distant sites were investigated by
tumor volume measurements and non-invasive fluores-
cent imaging. For this purpose, we administered 2
nmol/100 μL of IntegriSense 750 (Perkin Elmer, Inc.,
Waltham, Inc.) intravenously through the tail vein. After
24 h, imaging was performed at excitation 745 and emis-
sion 800 using In Vivo Extreme (Carestream Health
Inc., Rochester, NY). A reflectant image and x-ray CT
image were also acquired to establish anatomical land-
marks. Animals were euthanized by CO2 asphyxiation.
The tumors from metastatic sites and non-metastatic
xenografts were harvested and prepared as single-cell
suspensions as described below. To reproduce high-risk
aggressive disease, animals were injected with isolated
and well-characterized clones of aggressive cells derived
from individual metastatic sites, and observed for devel-
opment of metastatic tumors. Parallel experiments were
performed with cells derived and characterized from
non-metastatic xenografts.
Preparation of single-cell suspensions of tumor cells, cell
sorting, and ex vivo maintenance
To derive tumor cells from individual metastatic sites
and non-metastatic xenografts, we thoroughly minced
pre-weighed tumor samples in cell dissociation buffer
(DMEM media supplemented with 10 % FBS, penicillin/
streptomycin, 200 U/mL Collagenase type IV, and 0.6
U/mL dispase). A 5 ml serological pipet of titrated cell
suspension was allowed to incubate at 37 °C for 3 h for
enzymatic dissociation, with mechanical dissociation
every 15 min. At the end of the incubation, cells were
filtered through a 70 μm filter and subjected to density
centrifugation using Ficoll-Plaque Plus to separate viable
cells from dead cells and tissue debris. Cells collected
from the interface were diluted (1:3) in fresh DMEM:F12
with 10 % FBS and counted for viable cells using Count-
ess. Metastatic site derived aggressive cells (MSDACs)
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1 % N2 Supplement, 2 % B27 Supplement, 20 ng/ml
hPDGF, 100 ng/ml EGF, and 1 % antibiotic-antimycotic)
at 37 °C, 5 % CO2. Suspensions were then sequentially
characterized with karyotyping, whole genome array CGH
analysis, ex vivo tumorosphere-forming capacity, and
in vivo tumorigenicity.
Total RNA/miRNA Isolation and whole genome miRNA
microarray profiling
Total RNA/miRNA from parental SH-SY5Y, MSDACs,
and a manifold of metastatic tumors was extracted using
TRIzol reagent (Invitrogen) or miRNeasy kit (Qiagen),
following the manufacturer’s protocol. RNA concentra-
tion and quality were determined using the RNA 6000
Nano assay on the Agilent 2100 Bioanalyzer (Agilent
Technologies). miRNA expression profiles were per-
formed using the human miRNA One Array V4
(Phalanx Biotech) that includes 1,884 unique miRNA
probes and 144 experimental control probes. Each
unique probe has 3 features. Probes contain 100 % of
Sanger miRBase V18 miRNA content. Isolated miRNA
(500 ng) was labeled with Cy3 using a Kreatech ULS
miRNA labeling kit and hybridized using an miRNA One
Array V4 kit (Phalanx) following the manufacturer’s
protocol. Hybridized signals were detected by the micro-
array scanner G2600D (Agilent Technologies, Santa
Clara, CA, USA) and quantified using ImageQuant (GE
Healthcare Bio-Sciences, Pittsburgh, PA, USA). Complete
matrix of the whole genome miRNA expression and their
metadata are included in Additional files 6. Expression
profiles of each feature were background-subtracted, nor-
malized to internal U6 features, and compared between
groups using Prism (GraphPad Software, Inc., La Jolla,
CA, USA). To eliminate inter-animal variations that
could equivocate expression outcomes within the gr-
oup, we adopted non-metastatic control(s)→metastatic
tumor(s) traverse analysis between every sample ana-
lyzed. For this, expression profile of background sub-
tracted and array-normalized miRNAs of non-metastatic
primary xenograft control-1 was first individually com-
pared to the miRNA expression profiles of each aggres-
sive metastatic tumors and, the overall and/or >2-fold
up/down regulated miRNAs for each aggressive tumors
are computed. The comparison analysis was then per-
formed to identify miRNAs that were commonly up/
down regulated (both overall as well as >2-fold change)
across the aggressive tumors as opposed to control-1.
Next a similar detailed approach was utilized to obtain
the miRNAs that were commonly up/down regulated
(both overall and >2-fold) across the aggressive tumors
as opposed to non-metastatic primary xenograft control-
2. Finally, crisscross data comparison analysis was per-
formed between the data sets 1 and 2 to define themiRNAs that were up or down regulated in aggressive
metastatic tumors, ruling out any intra-group variations
associated equivocal outcomes. Commonly reorganized
metastamiRs (upregulated and downregulated) across the
manifold of metastatic tumors are further examined In-
genuity Pathway analysis, Target Scan, and miRBase to
determine the gene targets.miRNA qPCR
In order to validate the miRNA expression obtained
from whole genome profiling, expression of selected
metastamiRs, including hsa-miR-1224-3p, hsa-miR-1260
(both significantly upregulated), hsa-miR-125b, hsa-
miR-27b, hsa-miR-93 ,and hsa-miR-20a (all significantly
downregulated) were confirmed using QPCR. Hsa-miR-
U6 was used as an internal positive control. Briefly,
poly (A) tailed (Poly (A) tailing kit, Life Technologies,
Grand Island, NY, USA), miRNA was reverse transcribed
using miRNA EasyScript™ cDNA synthesis kit (Applied
Biological Materials Inc., Richmond, BC, Canada) as per
the manufacturer’s protocol. QPCR sampling was per-
formed in triplicate using an miRNA EasyScript™ cDNA
Synthesis Kit (Applied Biological Materials, Inc.) follow-
ing the manufacturer’s PCR conditions. U6 normalized
expression was compared with the non-metastatic
controls and expressed as a fold change. Group—wise
comparisons were performed with two-way ANOVA
with Tukey’s post-hoc correction (GraphPad Prism).
Similarly, correlations in the expression patterns ob-
tained from the whole genome profiling with the QPCR
results were performed using GraphPad Prism.Functional characterization of metastamiRs and target
analysis
To functionally characterize the identified miRNAs in
tumor progression and metastasis we adopted three se-
quential approaches. First, utilizing Ingenuity Pathway
Analysis (Ingenuity Systems, Inc.) we examined the
credible intermolecular interactions and their association
to cancer. Next, to underscore and identify metasta-
miRs’ relevance in tumor progression and to delineate
neuroblastoma-specific shifts, we used the miRCancer
(http://mircancer.ecu.edu) database, and compared the
expression profiles in various human cancers, including
neuroblastoma. Lastly, by extracting information from
the published literature, we examined the defined func-
tions of the miRNAs in the context of metastasis and
tumor progression. Three inter-linked databases, ingenu-
ity pathway analysis, miRBase, and microRNA.org, were
used for targeted analysis of the identified metastamiRs.
Extracted lists of targets were subsequently compared to
each other and select targets that played crucial roles
in metastasis and were regulated by more than one
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tional modulations.Immunoblotting
Total protein extraction and immunoblotting were per-
formed as described earlier [62]. In MSDACs and meta-
static tumors, we analyzed modulations in the altered
expression of identified targets playing crucial roles in
metastasis, including ADAMTS-1, pAKT1/2/3, AKT1/2/
3, ASK1, AURKβ, Birc1, Birc2, Bric5, β-CATENIN,
CASP8, CD54, CDK4, CREB, CTGF, CXCR4, CYCLIN-
D1, EGFR, pEGFR, ELK1, ESR1, CFOS, FOSB, FRA,
GRB10, pGSK3β, IL1α, JUND, kRAS, KRTAP1, MCP1,
MEGF10, MMP2, MMP3, MMP9, MMP10, MTA2,
MYB, cMYC, NF2, NOS3, pNOS3, P21, pP38, PTPN3,
CLEAVED PARP, PKC, SDF-1β, SEMA3D, SELE,
STAT3, TLR3, TNFα, TNFR1, and VEGF. Blots were
stripped and reblotted with either anti-α-tubulin or anti-
β-actin to determine equal loading of samples.Tissue microarray construction and quantitative
immunohistochemistry
All mouse tissue microarray construction procedures were
performed in the Stephenson Cancer Center-Cancer
Tissue Pathology Core. For mouse neuroblastoma TMA,
tumor tissues from non-metastatic xenograft-bearing ani-
mals and from multiple metastatic sites from high-risk
aggressive disease-bearing animals were printed in dupli-
cate. Immunohistochemical staining for GRB10, MYC,
SEMA3D, KRTAP1-1, and MEGF10 was performed utiliz-
ing an automated Leica Bond III according to the manu-
facturer’s protocol using the Bond™ Polymer Refine
detection system. Appropriate tissue morphologic/patho-
logic (H&E) controls and negative controls with no pri-
mary antibody (data not shown) were examined in
parallel. The slides were micro-digitally scanned using an
Aperio Scanscope (Aperio Technologies, Inc., Buffalo
Grove, IL, USA) slide scanner. This allows the assembly of
tissue collections in TMA with variable magnifications.
We constructed virtual slides with digital histology. The
digital images of the TMA were then analyzed for GRB10,
MYC, SEMA3D, KRTAP1-1 or MEGF10 specific positivity
using the Aperio TMALab™ software that is equipped with
highly advanced algorithms for IHC and stain intensity
including cytoplasmic-, nuclear-, membrane- and total-
staining Intensity and/or counts quantification. Auto-
mated staining positivity and intensity was quantified in
precisely located and identified (with grid/row/column co-
ordinates) individual cores within the TMA using protein
specific (GRB10, SEMA3D, KRTAP1-1-cytoplasmic;
MYC-nuclear; MEGF10-membranous) image analysis
algorithms. Core-specific metadata for the TMA was
exported to excel and the group-wise comparisons wereperformed with two-way ANOVA with Tukey’s post-hoc
correction (GraphPad Prism).
miRNA manipulations and quantitative high-
throughput confocal immunofluorescence: To define
the effect of characterized metastamiRs on the putative
target proteins, we adopted two approaches: (i) inhibited
hsa-miR-1224-3p or hsa-miR-1260 (both significantly up-
regulated) and (ii) functionally mimicked hsa-miR-125b,
hsa-miR-27b, hsa-miR-93 or hsa-miR-20a (all significantly
downregulated) and examined for the miRNA-dependent
modulations in protein targets. Transient transfection of
MSDACs with hsa-miR-125b-, hsa-miR-27b-, hsa-miR-
93- or hsa-miR-20a- mimics (MISSION® microRNA
Mimics, Sigma-Aldrich) as well as hsa-miR-1224-3p- and
hsa-miR-1260-inhibitors (MISSION® Synthetic miRNA In-
hibitors, Sigma-Aldrich) were carried out by using either
TurboFectin 8.0 reagent (Origene) or Neon electropor-
ation transfection system (Life Technologies). We exam-
ined the cellular localization and expression levels of
ADAMTS-1, ASK-1, CREB, FOSB, GRB10, EGFR, kRAS,
MMP2, MMP3/10, p38, AKT, PTPN3, STAT3, TNFα and
VEGFa in MSDACs using Operetta high content quantita-
tive confocal imaging. Paraformaldehyde fixed cells were
permeabilized (0.25 % Triton X-100), blocked, and labelled
with corresponding antibody. They were then tagged with
Alexa Fluor 488 conjugated anti-mouse or anti-rabblit
secondary antibody (Abcam). The nucleus was counter-
labeled with DAPI. At least sixty-three fields/well with a
minimum of 3Z planes were analyzed with integrated Col-
umbus image analysis software. Unbiased automated
batch analysis was performed and the cells-total number,
mean/well cell–Alexa Fluor intensity were computed.
Group-wise comparisons were performed with ANOVA
with Tukey’s post-hoc correction (GraphPad Prism).
Clinical outcome association analysis
We used the R2: microarray analysis and visualization
platform (http://r2.amc.nl) created by Dr. Jan Koster at
the Academic Medical Center (AMC), Amsterdam, to
examine the association of the metastamiRs’ key targets,
i.e., those that showed defined alterations in protein ex-
pression/phosphorylation with immunoblotting, with
overall survival of patients with neuroblastoma. This
web-based application correlates a select gene expres-
sion profile with clinical outcomes using samples from
various cohorts of patients, and permitted us to demon-
strate the significance of altered genes in high-risk
disease and their relevance to clinical outcomes. For this
study, we utilized a cohort of 88 untreated primary
human neuroblastoma samples and examined the prog-
nostic values for ELK1, CDK4, CREB1, MMP2, AURKβ,
FRA, MYB, JUND, BIRC5, AKT2, SELE, TNFα, NOS3,
ESR1, KRTAP1-1, MMP3, NF2, CXCR4, ADAMTS1,
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information on these patients include age group
(<=18 m – 48; >18 m – 40), gender (Male 53, Female
35), INSS (Stage 1 – 8, Stage 2 – 15, Stage 3 – 13, Stage
4 – 40, Stage 4S – 12), MYCN status (amplified 16,
non-amplified 72), recurrence/progression (yes 35, not
detected 53), alive (yes, 55, no 33) etc., (http://r2.amc.nl).
The association of each gene’s expression with the over-
all survival probability was plotted in Kaplan-Meier plots
constructed for a follow-up of 240 months.
Additional files
Additional file 1: Figure S1. Ingenuity interaction networks for the
miRNAs reorganized in aggressive high-risk metastatic neuroblastoma. All
networks identified by IPA converge at biological functions that endorses
metastatsis and, thereby signify their role as metastamiRs.
Additional file 2: Figure S2. Ingenuity pathway analysis: Heat map
showing the association of the identified metastamiRs in multiple tumor
systems. Box sizes correspond to the number of focus molecules and the
color intensity is the –log(p-value). Numerical labels in the boxes
corresponds to the tumor type.
Additional file 3: Figure S3. Kaplan Meier plots showing clinical
outcomes in a cohort of 88 neuroblastoma patients in association with
the expression pattern of metastamiRs’ protein targets, ELK1, CDK4,
CREB1, MMP2, AURKβ, FRA, MYB, JUND, BIRC5, AKT2, SELE, TNFα. All these
targets showed induced expression levels (except CREB1) in MSDACs
(compared to parental SH-SY5Y) and manifold of metastatic tumors
(compared with non-metastatic xenograft) as examined with
immunoblotting. Gene expression-associated clinical outcomes were
assessed using the web-based R2: microarray analysis and visualization
platform. Induced expression of ELK1, CDK4, MMP2, AURKβ, FRA, MYB,
JUND, BIRC5, AKT2, SELE and TNFα as well as decreased expression of
CREB1 corresponded to the poor overall survival in NB patients.
Additional file 4: Figure S4. Kaplan Meier plots showing clinical
outcomes in a cohort of 88 neuroblastoma patients in association with
the expression pattern of metastamiRs’ targets NOS3, ESR1, SELE,
KRTAP1-1, MMP3, NF2, ELK-1, CXCR4, ADAMTS-1, ICAM-1, EGFR and ATK-1.
All these targets showed induced expression levels in MSDACs
(compared to parental SH-SY5Y) and manifold of metastatic tumors
(compared with non-metastatic xenograft) as examined with
immunoblotting.
Additional file 5: Table S1. List of reorganized miRNAs (52 up
regulated and 22 down regulated), their defined (published evidence)
functions in the context of metastasis and tumor progression,
corresponding number of gene targets and the miRNA→metastatsis
citation index. Almost all of the miRNAs identified in high-risk metastatic
neuroblastomas has been well characterized in the perspective of
metastasis regulation and, could be classified as metastamiRs.
Additional file 6: Reorganization of metastamiRs in the evolution of
metastatic aggressive neuroblastoma cells.
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